title: Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism.
abstract: OBJECTIVE
  Is long-term (≥3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE?
  
  
  CONCLUSIONS
  Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality.
authors.affiliation: Department of Vascular Medicine, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Saskia
authors.initials: S
authors.lastname: Middeldorp
authors.affiliation: Department of Clinical Epidemiology, Biostatistics and Bioinformatics, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Hutten
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K